Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

This review aims to provide a comprehensive overview of the current understanding of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), including its incidence, risk factors, clinical presentation, and diagnostic criteria. The aim is to enhance awareness among healthcare professionals and patients about BIA-ALCL, its management strategies, and the importance of surveillance in individuals with breast implants.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare form of T cell lymphoma characterized by the presence of the CD30 biomarker. Although BIA-ALCL is more prevalent than other primary breast lymphomas, its incidence rate is extremely low. Textured implants have been associated with nearly all instances of BIA-ALCL. A significant proportion of BIA-ALCL patients exhibit an excellent prognosis after the extraction of the implants and capsules. Unfavorable outcomes are seen in instances of tumor bulk and implant capsule invasion.

This review provides an in-depth understanding of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), focusing on its incidence, risk factors, clinical presentation, diagnostic criteria, and imaging evaluation. BIA-ALCL management techniques, treatment modalities, effectiveness, and outcomes are examined to improve patient care and awareness.